Australia's QRxPharma Files NDA With U.S. FDA For Combo Opioid That Looks Safer Than Single Compounds
This article was originally published in PharmAsia News
Sydney-headquartered QRxPharma filed in late July its MoxDuo IR (morphine/oxycodone) NDA with U.S. FDA for the treatment of moderate to severe acute pain. The NDA was submitted under the 505(b)(2) pathway, which allows for historical data because the two components of the dual opioid are already approved. Interestingly, the morphine and oxycodone combo appears to be safer than the two single compounds
You may also be interested in...
As User Fee Date Nears, Australia’s QRxPharma Moves To POC For MoxDuo CR Formulation; Secures Actavis As Partner
The company looks to position its dual-opioid combination against Purdue Pharma’s OxyContin.
Cephalon Inc. announced March 29 that it has struck an agreement with the Australia-based biopharma ChemGenex Pharmaceuticals Ltd. to pay A$159 million ($US $163 million) for the piece of the company it doesn't already own
TOKYO - South African firm Aspen appears on track to finalize its months-long acquisition attempt of Australia's Sigma Pharmaceuticals, shifting away from its original offer for a full acquisition to a leaner deal in which Aspen will gain Sigma's pharmaceutical division